Indications And Dose
HIV-1 infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 707
Loading InternPractice…
Drug reference
HIV-1 infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 707
Scottish Medicines Consortium (SMC) decisions SMC No. SMC2093 The Scottish Medicines Consortium has advised (September 2018) that bictegravir with emtricitabine and tenofovir alafenamide (Biktarvy ®) is accepted for use within NHS Scotland for the treatment of adults infected with human immunodeficiency virus type 1 without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower. All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 3414 The All Wales Medicines Strategy Group has advised (December 2018) that bictegravir with emtricitabine and tenofovir alafenamide (Biktarvy ®) is recommended as an option for restricted use within NHS Wales for the Infection treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir, and who are either unsuitable for or unable to tolerate abacavir with dolutegravir and lamivudine (Triumeq ®). Bictegravir with emtricitabine and tenofovir alafenamide (Biktarvy ®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
PDF page 707
→Appendix 1: bictegravir. tenofovir alafenamide
PDF page 707
▶Common or very common Depression. diarrhoea. dizziness . fatigue. headache. nausea. sleep disorders ▶Uncommon Anaemia. angioedema. anxiety. arthralgia. flatulence. gastrointestinal discomfort. hyperbilirubinaemia. skin reactions. suicidal behaviour. vomiting
PDF page 707
Manufacturer advises use only if potential benefit outweighs risk.
PDF page 707
Manufacturer advises avoid in severe impairment—no information available.
PDF page 707
Manufacturer advises avoid if creatinine clearance is less than 30 mL/minute—limited information available.
PDF page 707
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 25 ▶Biktarvy (Gilead Sciences International Ltd) A Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 25 mg, Bictegravir 50 mg, Emtricitabine 200 mg Biktarvy 50mg/200mg/25mg tablets | 30 tablet P £879.51
PDF page 707
Missed doses Manufacturer advises if a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
PDF page 707
1 tablet once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 707